Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
General Manager of recently acquired national uropathology laboratory to lead
CAMBRIDGE, Mass., Oct. 1, 2013
CAMBRIDGE, Mass., Oct. 1, 2013 /PRNewswire/ --Metamark Genetics, Inc., a
leader in the discovery of molecular prognostic and diagnostic tests for
cancer, today announced that Cornelius J. Merlini, former general manager of
HealthTronics Laboratory Solutions (HLS), has been appointed Metamark's Senior
Vice President and Chief Commercial Officer. In August 2013, Metamark
acquired HLS, a national uropathology laboratory, from Endo Health Solutions,
Inc. Mr. Merlini will report to Metamark President and Chief Executive
Officer, Shawn M. Marcell, and will join the company's senior leadership team.
"We are pleased that Cornelius has joined Metamark. His exceptional
leadership, commercial acumen, and track record bringing paradigm-changing
products to market have produced transformational business growth," said Mr.
Marcell. "Cornelius already is an established leader of Metamark's
newly-acquired uropathology business, where he assembled a talented, dedicated
team – including a specialized national field sales force. This commercial
team nicely complements Metamark's innovative research and development
efforts, and will accelerate the launch of ProMark™, our novel prostate cancer
"Metamark's strong science engine fits perfectly with its new commercial and
operational machine," said Mr. Merlini. "ProMark™ could redefine the
management of early stage prostate cancer and become a standard test sought by
patients and ordered by urologists when making well-informed treatment
decisions. It is exciting to join a company that could change the way
prostate cancer is treated."
Mr. Merlini has over twenty-five years of life science experience across a
wide array of functions and businesses. Prior to HealthTronics Lab Solutions,
Mr. Merlini was SVP, Commercial Operations at Cord Blood Registry, a market
leader in cord blood stem cell banking. He spent ten years with increasing
marketing, management and franchise leadership responsibilities at Johnson &
Johnson, where he served most recently as Worldwide Vice-President of the
cardiovascular franchise for Johnson & Johnson's biopharmaceutical business.
Earlier, Mr. Merlini gained successful sales and sales leadership experience
with Marion Laboratories (now Sanofi-Aventis).
Metamark Genetics, Inc. is a privately held biotechnology company founded in
2007 to develop novel, function-based prognostic and diagnostic tests aimed at
improving cancer care. The company's proprietary genomic and proteomic
discovery platforms have yielded significant discoveries in several disease
areas, including prostate, colon and breast cancers. In early 2014, Metamark
plans to commercialize ProMark™ – its prostate cancer prognostic test –
through its Cambridge, Massachusetts CLIA-certified laboratory. For more
information, please visit the company's Website at www.metamarkgenetics.com.
Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.
SOURCE Metamark Genetics, Inc.
Contact: Anna Corfey, 617-583-1453
Press spacebar to pause and continue. Press esc to stop.